{"id":"NCT02394561","sponsor":"Novartis Pharmaceuticals","briefTitle":"A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)","officialTitle":"A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-10","primaryCompletion":"2017-06-08","completion":"2017-06-08","firstPosted":"2015-03-20","resultsPosted":"2019-04-23","lastUpdate":"2019-04-23"},"enrollment":434,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Type Psorisis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["AIN457"]}],"arms":[{"label":"Cw6-positive AIN457 300 mg","type":"EXPERIMENTAL"},{"label":"Cw6-negative AIN457 300 mg","type":"EXPERIMENTAL"}],"summary":"A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis","primaryOutcome":{"measure":"Percentage (%) of Patients Who Reach Psoriasis Area Severity Index (PASI) 90 at 16 Weeks - LOCF Approach (ITT Set)","timeFrame":"Baseline up to 16 weeks","effectByArm":[{"arm":"Cw6-positive AIN457 300 mg","deltaMin":80.4,"sd":null},{"arm":"Cw6-negative AIN457 300 mg","deltaMin":81.7,"sd":null}],"pValues":[{"comp":"OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":246},"commonTop":["Hypertension","Pruritus"]}}